Rosellini Scientific Partners with iSTAR Medical SA to Develop STARflo PLUSTM Implant for Glaucoma Treatment

Share Article

Rosellini Scientific collaborates with leading innovators to foster cutting-edge medical technologies.

Rosellini Scientific, LLC, is pleased to announce a partnership with iSTAR Medical SA to develop a novel implant technology for treating glaucoma patients. The STARflo PLUSTM system improves drainage and reduces intraocular pressure by combining biomaterials, biosensors and telemedicine technologies. iSTAR Medical SA, a Belgium-based spinout of Healionics Corporation, based the STARflo PlusTM system on their STAR® Biomaterial product.

Rosellini Scientific Benelux (RSB) is a Belgium-based subsidiary of Rosellini Scientific, LLC in Dallas, TX. The company will be developing a communication system to read data from miniature sensors implanted in the device. Belgium’s Region Wallonne government, in coordination with the region’s health competitiveness cluster BioWin, provided $5 million to fund the STARflowPLUSTM project, of which $1 million will be awarded to Rosellini Scientific Benelux.

"This is an exciting opportunity for Rosellini Scientific to partner with leading innovators in an environment that fosters cutting-edge medical technologies," stated Hartmut Spitaels, MBA, President of Rosellini Scientific Benelux. "With this partnership, we can leverage our platform technology and benefit from an efficient pathway to clinical presence. We aim at starting trials with leading clinicians in Belgium and extending further distribution in the EU."

In addition to the STARflo PlusTM system, Rosellini Scientific Benelux will also develop technologies and applications that interface with the nervous system to treat a variety of diseases, including atrial fibrillation, overactive bladder and brain cancers.

About Rosellini Scientific, LLC

Rosellini Scientific, LLC is an emerging leader in the development of implantable, wireless, electronic neurostimulation and implantable medical devices for the treatment of a variety of pathologies. The company and its founders have been a part of nearly $30 million in active implantable device development. Rosellini Scientific is currently developing therapeutic technologies for diverse applications including severe asthma, type 2 diabetes mellitus, painful diabetic peripheral neuropathy, overactive bladder and atrial fibrillation. RSB will be Rosellini Scientific’s third spinout and first in Europe. Rosellini Scientific previously spun-out MicroTransponder, Inc. in 2006, which developed wireless technology for the treatment of neurological disorders such as tinnitus and stroke. Large-scale, multi-center clinical trials of these devices, including a first-in-man clinical trial at the University of Antwerp, are ongoing.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Elissa Nadel
Rosellini Scientific

Visit website

Media

Rosellini Scientific Logo